Virtuozzo Acquires OnApp, Enabling More Comprehensive Intuitive Cloud Infrastructure Solutions for Service Providers
20.7.2021 11:00:00 EEST | Business Wire | Press release
Virtuozzo’s mission is to help shape the future of the cloud by empowering service providers with comprehensive, high performance, flexible and easy-to-use cloud infrastructure solutions supporting private, public and hybrid cloud use cases. To that end, Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced it is acquiring OnApp, a London-based software company focused on cloud solutions for service providers. The acquisition augments Virtuozzo’s existing cloud IaaS and PaaS products while expanding its regional market reach.
Future-proofed Cloud Flexibility, Simplicity and Automation
The combined technological and R&D strengths of both companies directly target the evolving needs of Cloud Service Providers (CSPs), Managed Service Providers (MSPs), and Hosting Providers focused on providing IaaS, PaaS and XaaS solutions for their customers.
The resulting solution stack will pair Virtuozzo’s easy-to-use virtualization, containerization, storage and orchestration capabilities with advanced features of OnApp’s flexible self-service management platform. In turn, service providers will gain access to today’s most intuitive and robust cloud infrastructure and platform solutions capable of supporting any cloud use case.
“Virtuozzo’s primary expertise has traditionally been in high-density server virtualization and software-defined storage. We have successfully expanded over the last few years into hyperconverged infrastructure as it is crucial to the market’s evolution,” said Alex Fine, Virtuozzo CEO. “Simple, flexible and smart access to those strong, fundamental technologies is core to the success of MSPs, CSPs and Hosting Providers and therefore, core to ours. OnApp shares that commitment and brings to Virtuozzo incredible engineering talent and complementary technologies that help us advance the cloud infrastructure industry as a whole. We’re proud and excited to have the OnApp team on board.”
Market Growth Driving Innovation
Timing and demand are key factors behind the acquisition. Synergy Research Group recently reported that cloud infrastructure demand reached $129 billion in 2020, growing 35% year over year. About a third of this market is owned by non-hyperscalers—local, regional and multi-national service providers. Those providers are the beneficiaries of Virtuozzo technology.
In parallel, 451 Research, a part of S&P Global Market Intelligence, recently discussed in its 2021 analysis Demand and Opportunity in the Alternative Cloud Provider Market a potential new opportunity for alternative CSPs, noting that they may find a role in larger multi-cloud portfolios and that “alternative can mean ‘in addition to’ rather than ‘instead of.’”1 Collectively, these reports suggest that alternative CSPs and MSPs are well-positioned to become partners of choice for customers shifting to modern cloud services.
“In addition to OnApp technical expertise in cloud orchestration, user interface and content delivery networks, Virtuozzo sees the value our highly talented staff brings to the table,” stated Ditlev Bredahl, CEO, OnApp. “Integration and evolution of the joint solution stack will be strongly beneficial to the customers of both companies.”
Terms of the transaction were not disclosed. Per the agreement, OnApp will continue operation as a division of Virtuozzo with OnApp’s staff integrating into Virtuozzo’s organizational structure. Business will continue as usual with Bredahl assisting with post-acquisition integration.
About OnApp
OnApp provides software and services that enable hosts, MSPs and telecoms providers to create and sell their own public, private and hybrid clouds. OnApp launched in July 2010, and to date has deployed more than 6,000 clouds for service providers in 93 countries. OnApp has 130 staff across the EU, U.S. and Asia-Pacific and is headquartered in London, UK. For more information, visit https://onapp.com.
About Virtuozzo
Virtuozzo (www.virtuozzo.com) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
1 Demand and Opportunity in the Alternative Cloud Provider Market, Liam Eagle, 451 Research, a part of S&P Global Market Intelligence. January 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005004/en/
Contact information
Heather Ailara/Deb Brown
211 Communications
+1.973.567.6040
heather@211comms.com
/
deb@211comms.com
Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
